Population-based investigation of relative clearance of digoxin in japanese patients by multiple trough screen analysis: An update

Journal of Clinical Pharmacology

Volumn 37, Issue 2, 1997, Pages 92-100

  Yukawa, Eiji ^a   Honda, Tomoo ^a   Ohdo, Shigehiro ^a   Higuchi, Shun ^a   Aoyama, Toshinobu ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; BODY WEIGHT; COMPUTER PROGRAM; CONGESTIVE HEART FAILURE; COST BENEFIT ANALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DATA ANALYSIS; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; ORAL DRUG ADMINISTRATION; PATIENT SELECTION; SCREENING; STEADY STATE;

EID: 0030997205     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04766.x     Document Type: Article

References (25)

1. Mooradian AD: Digitalis; an update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. Clin Pharmacokinet 1988;15:165-179.
2. Iisalo E: Clinical pharmacokinetics of digoxin. Clin Pharmacokinet 1977;2:1-16.
3. Aronson JK: Clinical pharmacokinetics of digoxin 1980. Clin Pharmacokinet 1980;5:137-149.
4. Dobbs RJ, O'Neill CJA, Deshmukh AA, Nicholson PW, Dobbs SM: Serum concentration monitoring of cardiac glycosides; How helpful is it for adjusting dosage regimens? Clin Pharmacokinet 1991;20:175-193.
5. Sheiner LB, Benet LZ: Premarketing observational studies of population pharmacokinetics of new drugs. Clin Pharmcol Ther 1985;38:481-487.
6. Yukawa E, Mine H, Higuchi S, Aoyama T: Digoxin population pharmacokinetics from routine clinical data: Role of patient characteristics for estimating dosing regimens. J Pharm Pharmacol 1992;44:761-765.
7. Beal SL, Sheiner LB, (eds.): NONMEM User's Guide. San Francisco: NONMEM Project Group, University of California at San Francisco, 1992.
8. Cockcroft DW, Gault MH: Prediction of creatine clearance from serum creatine. Nephron 1970;16:31-41.
9. Jelliffe RW: Creatinine clearance: bedside estimate. Ann Inter Med 1973;79:604-605.
10. Ochs HR, Bodem G, Greenblatt DJ: Effect of dose on bioavailability of oral digoxin. Eur J Clin Pharmacol 1981;19:53-55.
11. Waldorff S, Andersen JD, Heeboll-Nielsen N, Nielsen OG, Moltke E, Sorensen U, Steiness E: Spironolactone-induced changes in digoxin kinetics. Clin Pharmacol Ther 1978;24:162-167.
12. Fenster PE, Hager WD, Goodman MM: Digoxin-quinidine-spironolactone interaction. Clin Pharmacol Ther 1984;36:70-73.
13. Hori R, Miyazaki K, Mizugaki M, Ogata H, Goto M, Ichimura F, et al: Estimation of population pharmacokinetic parameters in the Japanese. Digoxin. The Japanese Journal of Therapeutic Drug Monitoring 1994;11:7-17.
14. Hedman A, Angelin B, Arvidsson A, Dahlqvist R: Digoxin-interactions in man: Spironolactone reduces renal but not biliary digoxin clearance. Eur J Clin Pharmacol 1992;42:481-485.
15. Yukawa E: New and simple method for estimating metildigoxin dosing regimens by multiple trough screen analysis. Int J Clin Pharmacol Ther 1995;33:605-611.
16. 1). J Pharmacol Exp Ther 1992;263:840-845.
17. Foukaridis GN: Influence of spironolactone and its metabolite canrenone on serum digoxin assays. Ther Drug Monit 1990;12:82-84.
18. Sheiner LB, Rosenberg B, Marathe VV: Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977;5:445-479.
19. Naafs MAB, van der Hoek C, van Duin S, Koorevaar G, Schopman W, Silberbusch J: Decreased renal clearance of digoxin in chronic congestive heart failure. Eur J Clin Pharmacol 1985; 29:249-252.
20. Sheiner LB, Beal SL: Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9:503-512.
21. Nicholson PW, Dobbs SM, Rodgers EM: Ideal sampling time for drug assays. Br J Clin Pharmacol 1980;9:407-470.
22. Dobbs RJ, Nicholson PW, Denham MJ, Dobbs SM, O'Neill CJA: Therapeutic drug monitoring of digoxin: Help or Hindrance? Eur J Clin Pharmacol 1986;31:491-495.
23. Koup JR, Jusko WJ, Elwood CM, Kohli RK: Digoxin pharmacokinetics: Role of renal failure in dosage regimen design. Clin Pharmacol Ther 1975;18:9-21.
24. Williams PJ, Lane J, Murray W, Mergener MA, Kamigaki M: Pharmacokinetics of digoxin-quinidine interaction via mixed-effect modelling. Clin Pharmacokinet 1992;22:66-74.
25. Bauer LA, Horn JR, Pettit H: Mixed-effect modeling for detection and evaluation of drug interactions: Digoxin-quinidine and digoxin-verapamil combinations. Ther Drug Monit 1996;18:46-52.